Rotigotine transdermal patch in Parkinson's disease: a narrative review of pharmacology, clinical evidence, special-population management, and health economics.
- 1Department of Pharmacy, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- 2Beijing North Medical Health Economic Research Center, Beijing, China.
- 3College of Business Administration, Shenyang Pharmaceutical University, Shenyang, China.
Abstract
Background
Parkinson's disease (PD) requires lifelong dopaminergic therapy, yet oral routes are frequently compromised by gastrointestinal dysfunction, dysphagia, and perioperative fasting. Abrupt withdrawal of oral dopaminergic drugs may precipitate severe motor deterioration or parkinsonism-hyperpyrexia syndrome. Rotigotine transdermal patch delivers 24-h continuous dopaminergic stimulation (CDS) via a non-ergot dopamine agonist (DA) formulation that bypasses first-pass metabolism and gastrointestinal absorption, and may be particularly useful when oral dopaminergic delivery becomes unreliable or is not possible.Objective
To synthesize published evidence on rotigotine pharmacology, clinical efficacy, management in vulnerable populations, safety, real-world effectiveness, and health economics, with emphasis on the incremental contribution of a scenario-based, Asia/China-inclusive, and pharmacy-oriented narrative relative to prior general reviews.Methods
Narrative review of randomized controlled trials, meta-analyses, regulatory documents, pharmacoeconomic models, and prospective observational studies identified through structured literature search and bibliographic screening.Results
Transdermal bioavailability is approximately 37% versus less than 5% for oral rotigotine. Pivotal Chinese trials SP0914 (early PD: UPDRS II + III -4.9 vs. -0.2) and SP1037 (advanced PD: placebo-adjusted off-time reduction -1.20 h/d [95% CI -1.83 to -0.57]; within-group change -2.36 h/d) demonstrated efficacy; meta-analyses support motor and selected non-motor benefits, including sleep, mood, and gastrointestinal tolerability, whereas swallowing-related signals remain preliminary and based mainly on small observational studies. Perioperative fasting, dysphagia, end-stage disease, and hepatorenal impairment represent clinically important scenarios in which non-oral delivery may be considered, although supporting evidence outside pivotal motor trials is often limited. Application-site reactions (ASRs) are the principal local adverse events; structured 14-day site rotation reduced ASR from 50.0% to 20.3% (P = 0.0373). Chinese cost-effectiveness analyses reported an incremental cost-effectiveness ratio of 1,118,617.81 CNY per quality-adjusted life year versus pramipexole immediate-release at market price, with price-sensitivity thresholds of 28.5% and 9.5% reductions.Conclusion
Rotigotine provides CDS for patients with PD when oral delivery is unreliable; individualized patient selection, structured pharmaceutical care, and updated pharmacoeconomic evaluation are warranted.
Related
- Whole-genome sequencing of 197 cases with Parkinson’s disease reveals novel pathogenic variants in the Indian population
- 3D CNN-CVAE and LSTM-guided de novo design of rotigotine derivatives targeting dopamine D1 and D3 receptors in restless legs syndrome
- Rotigotine Attenuates Mechanical Hypersensitivity in 6-OHDA-Lesioned Rats: Associations with D2/D3 Receptors and Spinal Glial NF-κB/p65 Signaling
- Human Skin Permeability Prediction by Machine Learning for Transdermal Drug Delivery
- Obesity prevalence and management insights using Adipoview a real time clinical obesity landscape indicator based on a population study
BibTeX
@article{sun2026rotigotine,
title = {{Rotigotine transdermal patch in Parkinson's disease: a narrative review of pharmacology, clinical evidence, special-population management, and health economics.}},
author = {Xuelin Sun and Dongfang Qian and Wenjing Zhao and Jingyi Zhang and Xin Hu and Yatong Zhang},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1933610},
url = {https://europepmc.org/article/MED/42903465},
note = {CC BY},
}
RIS
TY - JOUR
TI - Rotigotine transdermal patch in Parkinson's disease: a narrative review of pharmacology, clinical evidence, special-population management, and health economics.
AU - Xuelin Sun
AU - Dongfang Qian
AU - Wenjing Zhao
AU - Jingyi Zhang
AU - Xin Hu
AU - Yatong Zhang
PY - 2026
DA - 2026/10/06
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1933610
UR - https://europepmc.org/article/MED/42903465
AB - Background Parkinson's disease (PD) requires lifelong dopaminergic therapy, yet oral routes are frequently compromised by gastrointestinal dysfunction, dysphagia, and perioperative fasting. Abrupt withdrawal of oral dopaminergic drugs may precipitate severe motor deterioration or parkinsonism-hyperpyrexia syndrome. Rotigotine transdermal patch delivers 24-h continuous dopaminergic stimulation (CDS) via a non-ergot dopamine agonist (DA) formulation that bypasses first-pass metabolism and gastrointestinal absorption, and may be particularly useful when oral dopaminergic delivery becomes unreliable or is not possible.Objective To synthesize published evidence on rotigotine pharmacology, clinical efficacy, management in vulnerable populations, safety, real-world effectiveness, and health economics, with emphasis on the incremental contribution of a scenario-based, Asia/China-inclusive, and pharmacy-oriented narrative relative to prior general reviews.Methods Narrative review of randomized controlled trials, meta-analyses, regulatory documents, pharmacoeconomic models, and prospective observational studies identified through structured literature search and bibliographic screening.Results Transdermal bioavailability is approximately 37% versus less than 5% for oral rotigotine. Pivotal Chinese trials SP0914 (early PD: UPDRS II + III -4.9 vs. -0.2) and SP1037 (advanced PD: placebo-adjusted off-time reduction -1.20 h/d [95% CI -1.83 to -0.57]; within-group change -2.36 h/d) demonstrated efficacy; meta-analyses support motor and selected non-motor benefits, including sleep, mood, and gastrointestinal tolerability, whereas swallowing-related signals remain preliminary and based mainly on small observational studies. Perioperative fasting, dysphagia, end-stage disease, and hepatorenal impairment represent clinically important scenarios in which non-oral delivery may be considered, although supporting evidence outside pivotal motor trials is often limited. Application-site reactions (ASRs) are the principal local adverse events; structured 14-day site rotation reduced ASR from 50.0% to 20.3% (P = 0.0373). Chinese cost-effectiveness analyses reported an incremental cost-effectiveness ratio of 1,118,617.81 CNY per quality-adjusted life year versus pramipexole immediate-release at market price, with price-sensitivity thresholds of 28.5% and 9.5% reductions.Conclusion Rotigotine provides CDS for patients with PD when oral delivery is unreliable; individualized patient selection, structured pharmaceutical care, and updated pharmacoeconomic evaluation are warranted.
SN - 1663-9812
ER -